Veristat Launches Strategic Resourcing to Build Greater Flexibility in its Suite of...
Providing sponsors expert staff to accelerate milestones and support study success
Veristat Expands its Expertise and Scale across Biopharma and Medtech
Acquires Swiss-based multi-disciplinary consultancy SFL (Solutions for Life Sciences) to accelerate the development of and access to...
Veristat Appoints Joe Scott as Chief Financial Officer
Accomplished Financial Executive to Drive Company’s Next Phase of Growth
Veristat Supported Marketing Applications for 12% of all FDA Novel Drug Approvals in 2021
Bridging the Gap between Trial and Treatment by Supporting the Approval of Several Novel Therapies for Rare Diseases
Veristat Strengthens Regulatory Capabilities Across Europe and UK
Acquires Drug Development and Regulation (DDR), a regulatory consultancy led by former senior officer at European Medicines Agency (EMA)
Veristat Appoints Colleen Pelton Chief Talent Officer
Global Talent Executive to Advance Company’s Commitment to a Best-in-class Workforce
Veristat Announces New Investment Partner—WindRose Health Investors
Recapitalization Will Accelerate Strategic Growth to Help Sponsors Save and Improve the Lives of Patients
Veristat Congratulates Origin Biosciences for FDA Approval
Veristat Congratulates Origin Biosciences for FDA Approval of Nulibry during the Week of Rare Disease Day 2021
Veristat Expands Biometrics Capabilities by Acquiring SQN Clinical
Builds on a shared pedigree of data management, statistics and programming excellence across all phases of clinical trials
SOUTHBOROUGH, MA...